AHF Hails HRSA Stance on J&J’s Illegal Attack on 340B Program

WASHINGTON--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) welcomes the strong stand the U.S. Health Resources and Services Administration (HRSA) took today against Johnson & Johnson’s illegal actions that would destroy the 340B Drug Pricing Program. See HRSA Response to J&J's September 19, 2024 Letter

J&J’s illegal scheme will deny required 340B discounts to eligible safety net covered entities and instead provide rebates if and when it chooses. J&J’s scheme may or may not reimburse providers at a later date, cheating safety net providers, making every claim subject to dispute and protracted payment. J&J is violating the law and AHF is pleased that HRSA has swiftly responded.

Drug companies who want the lucrative opportunity to sell their medications to the multi-billion-dollar Medicaid and Medicare drug programs, by law, must offer discounts to eligible nonprofit healthcare providers, such as nonprofit rural hospitals, HIV and black lung disease clinics. If J&J doesn’t want to comply with the law, HRSA is saying that it will block it from selling its products to the taxpayer supported Medicaid and Medicare drug markets. J&J can’t unilaterally rewrite healthcare law.

AHF calls on the U.S. Congress to take swift action to explicitly outlaw this blatant illegal action which would blow a hole in the U.S. healthcare safety net.

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.1 million individuals across 47 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.